Category Archives: Vascular Endothelial Growth Factor Receptors

´╗┐Pharmacother. and more difficult strategy of creating gene knockouts. Second of all, microRNA targeting represents a novel and still undeveloped approach toward potential therapeutic applications. Oligonucleotide (ON) analogs inhibit microRNA function essentially by a steric block, RNase H-independent and RISC-independent, antisense mechanism through complementary binding of the ON to the microRNA sequence. The cellular outcome of such binding is still unclear, with reports arguing either in favor of a mechanism based on simple sequestration by stoichiometric complex formation between the mature microRNA and the ON inhibitor (Chan et al. 2005), or in favor of a yet unknown mechanism by which complex formation leads to degradation of the target microRNA (Krutzfeldt et al. 2005, 2007; Esau et al. 2006). A number of ON analog PLX-4720 types have been proposed that provide both metabolic stability as well as good RNA binding, two fundamental requirements for microRNA inhibition. Early literature reports showed that…

Read more